GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (AQSE:MYIG) » Definitions » Capex-to-Operating-Cash-Flow

Mydecine Innovations Group (AQSE:MYIG) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mydecine Innovations Group Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Mydecine Innovations Group's Capital Expenditure for the three months ended in Jun. 2024 was £0.00 Mil. Its Cash Flow from Operations for the three months ended in Jun. 2024 was £-0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Mydecine Innovations Group Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Mydecine Innovations Group's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Capex-to-Operating-Cash-Flow Chart

Mydecine Innovations Group Annual Data
Trend Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mydecine Innovations Group Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mydecine Innovations Group's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mydecine Innovations Group's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's Capex-to-Operating-Cash-Flow falls into.



Mydecine Innovations Group Capex-to-Operating-Cash-Flow Calculation

Mydecine Innovations Group's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -2.483
=N/A

Mydecine Innovations Group's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.004
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mydecine Innovations Group  (AQSE:MYIG) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Mydecine Innovations Group Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group Business Description

Traded in Other Exchanges
Address
1890 – 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group Headlines

No Headlines